Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The clinicaltrials.gov site has been updated for the Phase 2 schizophrenia trial.
https://classic.clinicaltrials.gov/ct2/show/NCT06245213?term=anavex&draw=2&rank=5
Good luck and GOD bless,
Tesla Cybertruck is the vehicle choice of celebrities across the U.S.
https://www.teslarati.com/tesla-cybertruck-celebrity-owner-list/
Good luck and GOD bless,
I think everyone needs to be careful with the following:
Blarcamesine DOES NOT Reverses Brain Volume Loss.
Blarcamesine Reduces Brain Volume Loss!!!
GOD bless.
From Stanford
One step back: Why the new Alzheimer’s plaque-attack drugs don’t work
https://scopeblog.stanford.edu/2024/03/13/why-alzheimers-plaque-attack-drugs-dont-work/
Good luck and GOD bless,
The trial is successful in meeting the co-primary endpoints if the significance of each endpoint is P < 0.05, or if the significance of only one co-primary endpoint is P < 0.025. If only one primary endpoint is significant at an a level of 0.025, then the secondary endpoint will be evaluated at the same level of 0.025. The trial was successful, since the differences in the least-squares mean (LSM) change from baseline to 48 weeks between the blarcamesine and placebo groups were -1.783 [95% CI, -3.314 to -0.251]; (P = 0.0226) for ADAS-Cog13, and -0.456 [95% CI, -0.831 to -0.080]; (P = 0.0175) for CDR-SB in patients with early Alzheimer’s disease.
In addition, validated biomarkers of amyloid beta pathology, plasma Aß42/40 ratio increased significantly (P = 0.048), demonstrating strong anti-amyloid effects of blarcamesine in Alzheimer’s disease patients, while MRI revealed significant reduction in brain volume loss, including whole brain (P = 0.0005), comparing treatment to placebo./quote]
https://www.anavex.com/post/anavex-sphase2b-3trialofblarcamesine-anavex-2-73-inpatientswithalzheimer-sdisease
Good luck and GOD bless,
An example of an embargo on a published peer reviewed paper and the information within the paper.
The work described has not been published previously (except in the form of an abstract and academic thesis), and it is not under consideration for publication elsewhere. The publication is approved by all authors and, tacitly or explicitly, by the responsible authorities where the work was carried out. If accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright holder.
The Anavex 3-71 schizophrenia trial
Active Comparator: ANAVEX3-71 30 mg TID It is an abbreviation for "ter in die" which in Latin means three times a day.
The first active treatment arm of the study during Part A (multiple ascending doses).
Active Comparator: ANAVEX3-71 60 mg TID It is an abbreviation for "ter in die" which in Latin means three times a day.
The second active treatment arm of the study during Part A (multiple ascending doses).
Placebo Comparator: ANAVEXX3-71 Placebo TID It is an abbreviation for "ter in die" which in Latin means three times a day.
The placebo arm of Part A (multiple ascending doses).
https://classic.clinicaltrials.gov/ct2/show/NCT06245213?term=anavex3-71&draw=2&rank=2
Good luck and GOD bless,
$5.12 at the close of trading
Volume: 984,093
Expect AVXL to close at or near the high of the day with over one million shares bought today.
Good luck and GOD bless,
Tesla produces 1,000 Cybertrucks’ worth of 4680 cells at Giga Texas last week
https://www.teslarati.com/tesla-1k-cybertrucks-4680-cells-giga-texas-last-week/
Good luck and GOD bless,
The Tesla Model Y was the best-selling vehicle in the world last year.
Good luck and GOD bless,
Tesla Model Y tops new study’s list of most-produced cars in 2023
https://www.teslarati.com/tesla-model-y-tops-most-produced-cars-2023/
Good luck and GOD bless,
Fed holds rates steady and maintains three cuts coming sometime this year
Good luck and GOD bless,
Anavex 3-71 is more potent than blarcamesine
Look at figure 2
https://www.mdpi.com/1422-0067/22/12/6359
Blarcamesine is very potent and the doses targeted in the Alzheimer’s trial were 30 mg per day and 50 mg per day.
For the schizophrenia trial the Anavex 3-71 target doses are 30 mg every 8 hours and 60 mg every eight hours.
With the potency of Anavex 3-71 and the dosing schedule, I expect OUTSTANDING EFFICACY from this Phase 2 schizophrenia trial.
Good luck and GOD bless,
Apparently you did not read the entire article that I supplied with the cost of treating schizophrenia.
The total cost per the article is $16,098 per year per patient.
The total cost for the USA would be over 2,800,000 times $16,098 or over $45 BILLION per year.
So treating men and women in the USA with Anavex 3-71 for schizophrenia has the potential to reduce medicare and medicare and insurance cost in the USA by tens of BiLLIONS of US dollars per year.
GOD bless,
There are 2,800,000 people in the USA who have schizophrenia. The average cost for drug treatment per person is $4,817.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533651/
Therefore the market for treating schizophrenia in the USA is over $13,487 BILLION per year.
There are BTW over 24,000,000 people in the world with schizophrenia.
Good luck and GOD bless,
YES!!!
Shell to close 1,000 gas stations to focus on EV charging deployment
https://www.teslarati.com/shell-close-gas-stations-ev-charging/
Good luck and GOD bless,
”…Schizophrenia is a persistent and often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide, including 2.8 million people in the U.S. …”
ABSOLUTELY GREAT NEWS regarding Anavex Life Sciences
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
https://www.anavex.com/post/anavex-life-sciences-initiates-placebo-controlled-u-s-phase-2-clinical-trial-of-anavex-3-71-in-schi
Good luck and GOD bless,
KarXT, Karuna’s Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications
The transaction will be accounted for as an asset acquisition resulting in an approximately $12 billion one-time
https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-Karuna-Therapeutics-Strengthening-Neuroscience-Portfolio/default.aspx
While KarXT from Karuna Therapeutics (KRTX), a muscarinic M1 receptor agonist, demonstrated weak benefits on cognitive impairments in individuals with Schizophrenia,[2] ANAVEX®3-71’s dual-pharmacological action on SIGMAR1 and M1 muscarinic receptors is implicated in its pro-cognitive effects in murine Alzheimer’s disease models and demonstrates its potential to treat cognitive and behavioral deficits in neurological diseases by affecting protein homeostasis in the central nervous system.
https://www.anavex.com/post/anavex-life-sciences-reports-publication-of-anavex-3-71-in-clinical-journal-confirming-pharmacokinet
Anavex 3-71 is the best drug for schizophrenia and other CNS diseases and/or conditions.
Good luck and GOD bless,
Roughly 6.5 million Americans suffer from Alzheimer’s dementia today, and that population is projected to double by 2050. You can bet that many of them and their family members will consider $100,000 a pittance if it means slowing the disease, even for just a few months.
Don’t buy the hype on new “breakthrough” Alzheimer’s treatments
The sober reality behind the effectiveness of two new drugs touted as Alzheimer's breakthroughs: lecanemab and donanemab.
https://bigthink.com/health/alzheimers-treatments-lecanemab-donanemab/
Good luck and GOD bless,
In an interview with Don Lemon, Tesla CEO Elon Musk teased the possibility of creating a flying car in conjunction with SpaceX.
Good luck and GOD bless,
The placebo-controlled Phase 2 ANAVEX®3-71-SZ-001 study, will consist of two-parts to explore multiple ascending doses in individuals with schizophrenia followed by a 28-day treatment period in a larger cohort. The study will utilize standard clinical outcome measures for schizophrenia including the Positive and Negative Symptoms Scale (PANSS) and novel electrophysiological biomarkers identified by the ERP Biomarker Qualification Consortium for use in schizophrenia clinical trials.
Anavex 3-71 taken every 8 hours during this trial.
Good luck and GOD bless,
The FDA can approve Anavex 3-71 immediately from this Phase 2 trial for schizophrenia.
The FDA has in FACT approved drugs directly as the result of Phase 2 trials.
https://www.alzforum.org/news/community-news/fda-approves-als-drug-phase-2-data
Good luck and GOD bless,
These doses are quite high and they are given every 8 hours to the participants in the schizophrenia trial. In the active cohorts they will be taking Anavex 3-71, which is at least an order of magnitude or two orders of magnitude more potent than any similar drug.
The Anavex 3-71 (formerly known a AF710b) Phase 2 schizophrenia trial has the following active arms
Active Comparator: ANAVEX3-71 30 mg TID: ter in die: three times a day.
Active Comparator: ANAVEX3-71 60 mg TID: ter in die: three times a day.
Placebo Comparator: ANAVEXX3-71 Placebo TID: ter in die: three times a day.
EXPECT VERY ANAVEX 3-71 TO BE HUGELY EFFECTIVE AT EVEN THE LOWEST DOSES!!!
https://classic.clinicaltrials.gov/ct2/show/NCT06245213?term=anavex+3-71&draw=2&rank=2
Good luck and GOD bless,
This is ABSOLUTELY GREAT NEWS for Anavex Life Sciences
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
https://www.anavex.com/post/anavex-life-sciences-initiates-placebo-controlled-u-s-phase-2-clinical-trial-of-anavex-3-71-in-schi
Good luck and GOD bless,
The classical clinicaltrials.gov website for the Anavex 3-71 schizophrenia trial
https://classic.clinicaltrials.gov/ct2/show/NCT06245213?term=anavex+3-71&draw=2&rank=2
Good luck and GOD bless,
This is a very quick trial
Enrollment (Estimated)
40
https://clinicaltrials.gov/study/NCT06245213?intr=ANAVEX3-71&rank=2
Good luck and GOD bless,
The Anavex 3-71 (formerly known a AF710b) Phase 2 schizophrenia trial has the following active arms
Active Comparator: ANAVEX3-71 30 mg TID: ter in die: three times a day.
Active Comparator: ANAVEX3-71 60 mg TID: ter in die: three times a day.
Placebo Comparator: ANAVEXX3-71 Placebo TID: ter in die: three times a day.
These doses are quite high and they are given every 8 hours to the participants in the trial.
EXPECT VERY ANAVEX 3-71 TO BE HUGELY EFFECTIVE AT EVEN THE LOWEST DOSES!!!
https://classic.clinicaltrials.gov/ct2/show/NCT06245213?term=anavex+3-71&draw=2&rank=2
Good luck and GOD bless,
The sigma-1 receptor located in MAM is a Ca2+-sensitive molecular chaperone that can regulate a variety of neurotransmitter systems. There is increasing evidence that the sigma-1 receptor is involved in the pathobiology neuropsychiatric diseases such as schizophrenia and depression.
https://academic.oup.com/schizophreniabulletin/article/48/2/474/6447503#;;
Good luck and GOD bless,
Pre-clinical models, postmortem and neuroimaging studies all support a role for muscarinic receptors in the molecular pathology of schizophrenia. From these data it was proposed that activation of the muscarinic M1 and/or M4 receptor would reduce the severity of the symptoms of schizophrenia.
https://www.frontiersin.org/articles/10.3389/fncel.2023.1124333/full#:~:text=Pre%2Dclinical%20models%2C%20postmortem%20and,of%20the%20symptoms%20of%20schizophrenia.
The deficits in M1 receptor expression are brain region-specific as M1 receptor-expressing neurons are reduced in the cortex, but not thalamus or hippocampus, of schizophrenia patients compared to controls
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006961/#:~:text=The%20deficits%20in%20M1%20receptor,compared%20to%20controls%20%5B101%5D.
Muscarinic receptors are anatomically positioned in cortical and subcortical areas and modulate dopaminergic and glutamatergic neurotransmission thought to be dysfunctional in schizophrenia. Neurochemical studies have shown that dopamine and muscarinic receptors reciprocally modulate one another.
https://pubmed.ncbi.nlm.nih.gov/12769625/#:~:text=Muscarinic%20receptors%20are%20anatomically%20positioned,receptors%20reciprocally%20modulate%20one%20another.
Anavex 3-71 (formerly known as AF710b) activates agonizes the muscarinic receptor.
https://www.anavex.com/post/anavex-life-sciences-announces-phase-2-clinical-trial-anavex-3-71-schizophrenia
Good luck and GOD bless,
Expect over 2 million shares bought today with AVXL closing green.
Good luck and GOD bless
“The Best-Selling Car in the World is Made in America”
https://www.teslarati.com/tesla-flexes-model-y-achievements-cybertruck-towing-advertisement/
Good luck and GOD bless,
Elon Musk’s xAI has officially open-sourced Grok
https://www.teslarati.com/elon-musk-xai-open-sourced-grok/
Good luck and GOD bless,
The work described has not been published previously (except in the form of an abstract and academic thesis), and it is not under consideration for publication elsewhere. The publication is approved by all authors and, tacitly or explicitly, by the responsible authorities where the work was carried out. If accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright holder.
You are WRONG.
The development and phenotyping of animal models is indeed essential in Alzheimer's disease-related research as valid models enable the appraisal of early pathological processes – which are often not accessible in patients, and subsequent target discovery and evaluation.
McGill-APP homozygous Tg rats (n = 22) express the human APP751 gene carrying the Swedish and the Indiana mutations under the control of the murine Thy1.2 promoter (Flores-Aguilar et al., 2022, Iulita et al., 2014, Leon et al., 2010, Wilson et al., 2016). Age-matched wild-type (wt) littermates rats (n = 22), derived from the same breeding scheme (heterozygous × heterozygous), were used as controls.